We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+11.94%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.64B
AUM Growth
-$192M
(-10%)
Cap. Flow
-$336M
Cap. Flow
% of AUM
-20.47%
Top 10 Holdings %
Top 10 Hldgs %
58.46%
Holding
59
New
16
Increased
10
Reduced
9
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$131M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$83.7M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$83M |
| 4 |
Eli Lilly
LLY
|
+$66M |
| 5 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$63.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$122M |
| 2 |
Quest Diagnostics
DGX
|
+$83.2M |
| 3 |
HOLX
Hologic
HOLX
|
+$79.3M |
| 4 |
Edwards Lifesciences
EW
|
+$67.8M |
| 5 |
AKRX
Akorn Inc
AKRX
|
+$59.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.82% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$18.4B
| $137M | 8.32% |
1,081,500
+51,500
| +5% | +$6.36M |
|
|
2
Cigna
CI
$76.1B
| $130M | 7.94% |
+1,000,000
| New | +$131M |
|
3
Biogen
BIIB
$30.7B
| $117M | 7.15% |
375,000
-100,000
| -21% | -$29.6M |
|
|
4
Edwards Lifesciences
EW
$50B
| $109M | 6.61% |
2,700,000
-1,800,000
| -40% | -$67.8M |
|
5
Labcorp
LH
$25.9B
| $103M | 6.28% |
873,000
-407,400
| -32% | -$48M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $79.7M | 4.85% |
+650,000
| New | +$83.7M |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $77.1M | 4.7% |
+4,250,000
| New | +$83M |
|
|
HOLX
8
DELISTED
Hologic
HOLX
| $73.8M | 4.5% |
1,900,000
-2,100,000
| -53% | -$79.3M |
|
9
Encompass Health
EHC
$11B
| $66.9M | 4.08% |
2,074,050
+251,400
| +14% | +$8.15M |
|
|
10
Eli Lilly
LLY
$1.03T
| $66.2M | 4.03% |
+825,000
| New | +$66M |
|
|
QGENF
11
DELISTED
QIAGEN NV
QGENF
| $62.4M | 3.8% |
2,275,000
-225,000
| -9% | -$6.17M |
|
|
MNK
12
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $61.1M | 3.72% |
+875,000
| New | +$63.3M |
|
13
Incyte
INCY
$24.9B
| $56.6M | 3.45% |
+600,000
| New | +$50.6M |
|
14
Merck
MRK
$321B
| $49.9M | 3.04% |
838,400
+536,419
| +178% | +$31.4M |
|
|
BCR
15
DELISTED
CR Bard Inc.
BCR
| $44.9M | 2.73% |
+200,000
| New | +$45M |
|
|
SYNH
16
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $44.6M | 2.72% |
1,000,000
+600,000
| +150% | +$26M |
|
17
Cardinal Health
CAH
$53.2B
| $40.8M | 2.49% |
+525,000
| New | +$42.4M |
|
18
Acadia Healthcare
ACHC
$2.62B
| $38.2M | 2.32% |
770,000
+85,780
| +13% | +$4.47M |
|
|
PRAH
19
DELISTED
PRA Health Sciences, Inc.
PRAH
| $38.1M | 2.32% |
675,000
+148,300
| +28% | +$7.27M |
|
|
20
CALL
Biogen
BIIB
$30.7B
| $31.3M | 1.91% |
+100,000
| New | +$29.6M |
|
21
Collegium Pharmaceutical
COLL
$1.17B
| $27M | 1.64% |
1,400,000
+75,000
| +6% | +$891K |
|
22
Pacira BioSciences
PCRX
$1.06B
| $25.5M | 1.55% |
744,280
+494,280
| +198% | +$19.4M |
|
|
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
| $25.2M | 1.54% |
700,000
-1,950,000
| -74% | -$41.8M |
|
|
CVRS
24
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $22.2M | 1.35% |
19,981,655
| – | – |
|
25
Perrigo
PRGO
$1.43B
| $18.2M | 1.11% |
+197,300
| New | +$18.2M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2016 Portfolio in Review
As of Q3 2016, HealthCor Management held 59 positions worth $1.64B, down 10% from $1.83B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
HealthCor Management withdrew a net $336M in Q3 2016, closing 23 positions and reducing 9 holdings. Its most notable exit was Aetna Inc, an estimated $122M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 78% a quarter earlier, followed by Financials.
Against the trend, HealthCor Management opened a new position in Cigna worth $130M.
- HealthCor Management's largest Q3 2016 buy was Cigna: 1,000,000 shares worth $130M.
- HealthCor Management added most to Merck in Q3 2016, an estimated $31.4M increase.
- HealthCor Management's biggest Q3 2016 reduction was Quest Diagnostics, cutting an estimated $83.2M.
- HealthCor Management fully exited Aetna Inc in Q3 2016, selling an estimated $122M.
- HealthCor Management's ten largest holdings make up 58% of its $1.64B portfolio in Q3 2016.
- HealthCor Management opened 16 new positions and closed 23 in Q3 2016.
- HealthCor Management's portfolio value fell 10% quarter-over-quarter to $1.64B.
Based on HealthCor Management's 13F filing for Q3 2016, filed 14 Nov 2016.